{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:39:34Z","timestamp":1781015974538,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0539-3","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T10:31:12Z","timestamp":1480588272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0790-047X","authenticated-orcid":false,"given":"Ghayath","family":"Janoudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Amegatse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chander","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"539_CR1","unstructured":"CADTH. Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives. Ottawa; CADTH; 2013 Oct [updated 2016 Feb]. (Environmental scan; issue 42)"},{"issue":"6","key":"539_CR2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","volume":"18","author":"T Richter","year":"2015","unstructured":"Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare disease terminology and definitions\u2014a systematic global review: report of the ISPOR rare disease special interest group. Value Health. 2015;18(6):906\u201314.","journal-title":"Value Health"},{"key":"539_CR3","unstructured":"Government of Canada. Archived - Minister Ambrose Announces Patient Involvement Pilot for Orphan Drugs - Canada News Centre. Available from: http:\/\/news.gc.ca\/web\/article-en.do?nid=873619 . Accessed Apr 2016"},{"key":"539_CR4","unstructured":"CADTH. The CADTH Common Drug Review \u2013 Myths Versus Facts. Available from: https:\/\/www.cadth.ca\/media\/cdr\/cdr-pdf\/cdr_myths_facts_e.pdf . Accessed Nov 2016."},{"key":"539_CR5","unstructured":"CADTH. CADTH Consultation \u2013 Drugs for Rare Diseases, CDR Update \u2013 Issue 94. Available from: https:\/\/www.cadth.ca\/cdr-update-issue-94 . Accessed Apr 2016"},{"key":"539_CR6","unstructured":"CADTH. Update on the CADTH approach to the review of drugs for rare diseases and integration of these reviews into the CADTH Common Drug Review process, CDR Update \u2013 Issue 103. Available from: https:\/\/www.cadth.ca\/cdr-update-issue-103 . Accessed Apr 2016."},{"key":"539_CR7","unstructured":"Orphanet Report Series - Prevalence of rare diseases: Bibliographic data - July 2015 - Number 2. http:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf . Last Accessed Jan 2016."},{"key":"539_CR8","unstructured":"CADTH. Common Drug Review Reimbursement recommendations Options and Deliberative Framework \u2014 effective November 21, 2012, CDR Update \u2013 Issue 83. Available from: https:\/\/www.cadth.ca\/cdr-update-issue-83 . Accessed Apr 2016."},{"key":"539_CR9","unstructured":"The Global Gene Project. RARE Diseases: Facts and Statistics. Available from: https:\/\/globalgenes.org\/rare-diseases-facts-statistics\/ . Accessed Apr 2016 CADTH. CADTH Consultation \u2013 Drugs for Rare Diseases, CDR Update \u2013 Issue 94. Available from: https:\/\/www.cadth.ca\/cdr-update-issue-94 . Accessed Apr 2016"},{"key":"539_CR10","unstructured":"Hadjivasiliou A. Orphan drug report 2014. Available from: http:\/\/info.evaluategroup.com\/rs\/evaluatepharmaltd\/images\/2014OD.pdf . Accessed Apr 2016."},{"key":"539_CR11","unstructured":"Canadian Organization for Rare Disorders (CORD). We believe that now is the time to act to provide hope and treatment to Canadians and their families who are impacted by a rare disease. Available from: https:\/\/www.raredisorders.ca\/our-work\/ . Accessed Apr 2016."},{"key":"539_CR12","unstructured":"CADTH. Recommendation Framework for CADTH Common Drug Review and pan-Canadian Oncology Drug Review Programs. Ottawa; CADTH; 2016 Mar. Available from: https:\/\/www.cadth.ca\/media\/cdr\/templates\/pre-sub-phase\/CDR_pCODR_recommendations_framework.pdf . Accessed Apr 2016."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T01:00:18Z","timestamp":1498352418000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-016-0539-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0539-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"164"}}